ArticleFrontiers in pharmacology2017

Adoption of Biosimilar Infliximab for Rheumatoid Arthritis, Ankylosing Spondylitis, and Inflammatory Bowel Diseases in the EU5: A Budget Impact Analysis Using a Delphi Panel.

Tim A Kanters et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.